Information Provided By:
Fly News Breaks for April 20, 2016
SCMP
Apr 20, 2016 | 09:03 EDT
Roth Capital analyst Michael Higgins says Sucampo's Phase 2 trial with cobiprostone failed to produce a significant benefit in patients suffering from refractory heartburn. The analyst views the recent weakness in the company's shares as a buying opportunity, adding that he expects positive results from a Phase 3 trial in kids suffering from constipation in the second half of 2016. The analyst reiterates a Buy rating and $29 price target.
News For SCMP From the Last 2 Days
There are no results for your query SCMP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.